Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 7/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.38 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650276 | 0.90 | SLC16A3 (0.42) | SLC16A3MAPK1MAPK14HSD11B1CXCR4 | |
| SCHEMBL927777 | 0.72 | SLC16A3 (0.64) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL7056007 | 0.72 | SLC16A3 (0.70) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL928767 | 0.71 | SLC16A3 (0.65) | SLC16A3SLC16A1 | |
| Bindarit SCHEMBL29387325 | 0.70 | SLC16A3 (1.00) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL928717 | 0.67 | SLC16A3 (0.87) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL927364 | 0.62 | SLC16A3 (0.81) | SLC16A3SLC16A1MCTS1ALDH1A1 | |
| SCHEMBL1650719 | 0.61 | SLC16A3 (0.72) | SLC16A3SLC16A1MCTS1ALDH1A1 | |
| Nafenopin SCHEMBL184232 | 0.61 | MAPK1 (1.00) | MAPK1MAPK14ALDH1A1 | |
| SCHEMBL6423382 | 0.61 | CHRNA7 (0.51) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS INC (CA) | 2019-11-07 | — | — | US | disclosed |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| EP-3310353-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | Translatum Medicus, Inc. (CA) | 2018-04-25 | — | — | EP | disclosed |
| EP-3181551-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-06-21 | — | — | EP | disclosed |
| EP-2254869-B1 | NEUE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 UND P40 | ACRAF (IT) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016203313-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2016-12-22 | — | — | WO | disclosed |
| EP-2254870-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | ACRAF (IT) | 2016-02-24 | — | — | EP | disclosed |
| US-8835481-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8283348-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2012-10-09 | — | — | US | disclosed |
| US-20110160205-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2011-06-30 | — | — | US | disclosed |
| US-7919518-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-04-05 | — | — | US | disclosed |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| US-20100311744-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2010-12-09 | — | — | US | disclosed |
| EP-2254869-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254870-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009109618-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109613-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | SLC16A3 4100/4885MAPK1 3820/4885MAPK14 4401/4885 |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | SLC16A3 4100/4885MAPK1 3820/4885MAPK14 4401/4885 |
| US-20110160205-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2368/4885MAPK1 1211/4885MAPK14 2490/4885 |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2368/4885MAPK1 1211/4885MAPK14 2490/4885 |
| US-20100311744-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2368/4885MAPK1 1211/4885MAPK14 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.